U.S. starts national Medicare coverage policy review for Biogen's Aduhelm

U.S. starts national Medicare coverage policy review for Biogen's Aduhelm
07/12/2021 22:09
(Reuters) -The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc's Alzheimer's drug, Aduhelm, that was recently approved by the country's health regulator.
The Centers for Medicare & Medicaid Services (CMS) expects to give a proposed decision within 6 months and a final decision within 9 months. (https://go.cms.gov/3hzMa6H)
Aduhelm is priced at $56,000 per year, which could represent significant spending for the government's Medicare program for people aged 65 and older.
Currently, coverage for the drug is determined at the local level by Medicare administrative contractors, who represent 12 jurisdictions across the country.

Related Keywords

New York ,United States ,Bengaluru ,Karnataka ,India ,Shounak Dasgupta ,Trisha Roy ,Caroline Humer ,Biogen Inc Alzheimer ,Centers For Medicare Medicaid Services ,Reuters ,Biogen Inc ,Medicaid Services ,புதியது யார்க் ,ஒன்றுபட்டது மாநிலங்களில் ,பெங்களூரு ,கர்நாடகா ,இந்தியா ,ஷ்ௌுனாக் தாஸ்குப்தா ,திரிஷா ராய் ,பயோஜென் இன்க் முதுமறதி ,மையங்கள் க்கு மருத்துவ மருத்துவ உதவி சேவைகள் ,ராய்ட்டர்ஸ் ,பயோஜென் இன்க் ,மருத்துவ உதவி சேவைகள் ,